Overactive bladder (OAB)
Conditions
Interventions
Imidafenacin 0.2mg/day
Sponsors
Kameda Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)OABSS Q3(urgency) score >=1 2)ICIQ-SF Q1(Frequency of urinary incontinence) score >=2 3)Patients from whom we have received written consent
Exclusion criteria
Exclusion criteria: 1)use of prohibited drugs within the past 2 weeks 2)use of prohibited therapies within the past 8 weeks 3)presence of urinary retention 4)residual urine volume >= 100 mL 5)a urinary catheter in place or intermittent use of urethral catheterization 6)urethral stenosis, active urinary tract infection, urinary calculus, interstitial cystitis 7)serious hepatic impairment, renal impairment cardiac disease 8)pyloric/duodenal/intestinal obstruction or paralytic ileus 9)decreased gastrointestinal motility or tension 10)angle-closure glaucoma 11)severe myasthenia gravis 12)polyuria 13)severe cognitive impairment 14)lack of consenting ability 15)presence of any other conditions that required preclusion in the opinion of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the number of urinary incontinence episodes at 8-10 weeks after the administration | — |
Secondary
| Measure | Time frame |
|---|---|
| OABSS, ICIQ-SF, IPSS-QOL, number of urine pad exchanges, urodynamics, and incidence of adverse events | — |
Countries
Japan
Contacts
Public ContactMasayoshi Nomura
Kameda Medical Center Urogynecology center
Outcome results
None listed